Suvoda introduces AI assistant 'Sofia' to streamline clinical trial management.

From many clicks to one query, drug supply managers can more quickly access, analyze, and visualize the trial supply data they need.PHILADELPHIA, March 5, 2025 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, today announced the early adopter launch of Sofia, an artificial intelligence assistant designed to simplify how study teams access and review clinical trial information.Sofia is available on the Suvoda Platform and can be enabled by sponsors looking to provide drug supply managers with efficient access to vital information through an intuitive chat interface, reducing what were once multi-screen, multi-click processes to simple conversations."When creating Sofia, we asked ourselves: What if clinical trial staff had an AI assistant that could alleviate their administrative burdens?" said E.K. Koh, Chief Product Officer at Suvoda. "Sofia became our answer. It's an exciting opportunity to streamline the management of clinical trials."Built with Suvoda's commitment to reliability and security, Sofia brings greater efficiency to clinical trial operations, while adhering to data privacy and other regulatory requirements in clinical research.Sofia's key capabilities include:Streamlines Information Retrieval: Users access trial information through natural language queries that simplify navigation. They can now easily find answers that otherwise would span multiple screens, putting information they need at their fingertips.Users access trial information through natural language queries that simplify navigation. They can now easily find answers that otherwise would span multiple screens, putting information they need at their fingertips

It follows after Suvoda launched its own purpose-built software platform designed to provide a seamless way for drug trial sponsors and sites to manage data across sites.